A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI‐2173 in patients with chronic hepatitis B virus infection

ATI‐2173 is an active site polymerase inhibitor nucleotide in development as part of a potentially curative regimen for chronic hepatitis B virus (HBV) infection. This study evaluated the safety, tolerability, pharmacokinetics (PK) and antiviral activity of ATI‐2173. This was a phase 1b, randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Squires, Katherine E., Ogilvie, Lauren, Jucov, Alina, Anastasiy, Igor, Ghicavii, Nelli, Huguet, Jade, Melara, Rebeca, Constantineau, Martin, De La Rosa, Abel, Mayers, Douglas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092119/
https://www.ncbi.nlm.nih.gov/pubmed/36201354
http://dx.doi.org/10.1111/jvh.13753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092119/
https://www.ncbi.nlm.nih.gov/pubmed/36201354
http://dx.doi.org/10.1111/jvh.13753

Ejemplares similares